GeoVax Labs, Inc. (Nasdaq: GOVX) has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026. The request has stayed any suspension or delisting action, allowing GeoVax’s common stock to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through the hearing and any extension period granted by the Panel. At the hearing, GeoVax intends to present its plan to regain and maintain compliance with Nasdaq listing standards.
This news matters because a Nasdaq delisting could severely limit GeoVax’s access to public capital, reduce liquidity for shareholders, and undermine the company’s ability to fund its expensive clinical-stage programs. Maintaining the listing is critical for a clinical-stage biotechnology company that relies on investor confidence to advance its pipeline. David Dodd, Chairman and CEO, stated, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution.”
GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. The company also continues to pursue manufacturing and product innovations intended to support broader access and preparedness, while evaluating strategic partnerships and funding opportunities aligned with its development priorities.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
The implications of this announcement extend beyond the immediate listing issue. GeoVax’s ability to continue developing GEO-MVA and Gedeptin depends on securing adequate financing. A successful Nasdaq appeal would help preserve the company’s access to capital markets, which is essential for funding the planned Phase 3 trial for GEO-MVA and further clinical development of Gedeptin. Moreover, the company’s focus on vaccine supply resilience, biodefense preparedness, and expanded global access aligns with growing governmental and global health priorities, potentially opening doors to non-dilutive funding and strategic partnerships.
For more information, visit www.geovax.com. The original release can be viewed on www.newmediawire.com.
